Abstract:BACKGROUND Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and obliterative pulmonary vascular remodeling that result in right heart hypertrophy, failure and premature death. One of the hallmarks of PAH is vascular fibrosis, an excessive deposition of extracellular matrix components (most notably collagen) in the vessel wall, which has been shown to have an important role in the pathogenesis of severe vascular remodeling. Our goal is to gain a better understanding of the mechanisms underlying pulmonary vascular fibrosis seen in IPAH patients in order to identify potential new drug target(s) to inhibit pulmonary vascular fibrosis and thereby prevent/reverse vascular remodeling for treatment of PAH. METHODS Employing the mice with Tie2 Cre‐mediated deletion of Egln1 which encodes hypoxia‐inducible factor prolyl hydroxylase 2, PHD2 ( Egln1 Tie2Cre ), and double knockout mice with Tie2 Cre‐mediated genetic deletions of both Egln1 and Hif1a (EH1) or Egln1 and Hif2a (EH2), we studied the role of PHD2 deficiency and HIF activation in inducing pulmonary vascular fibrosis. Trichrome staining was used to quantify pulmonary vascular fibrosis. Quantitative RT‐PCR analysis and immunostaining were carried out to define the molecular mechanisms of vascular fibrosis associated with PAH in Egln1 Tie2Cre mice. RESULTS Similar to IPAH lungs, mice inactivated for PHD2 in endothelial cells exhibited obliterative vascular remodeling with massive collagen deposition in the vessel wall as observed in Figure 1A . There was however no marked increase of interstitial fibrosis in Egln1 Tie2 lungs. Intriguingly, pulmonary vascular fibrosis was inhibited by genetic deletion of HIF2α but not HIF1α, suggesting an important role of activation of HIF2α secondary to PHD2 deficiency in mediating pulmonary vascular fibrosis. Quantitative RT‐PCR analysis revealed a marked increase of fibrotic markers such as collagen 1α1, 1α2 and 3α1 in Egln1 Tie2Cre mouse lungs, which was inhibited in EH2 mouse lungs. Another important feature of vascular fibrosis is the presence of myofibroblasts, which are responsible for extracellular matrix (ECM) production and accumulation. Immunostaining demonstrated prominent expression of periostin, a marker for myofibroblasts in Egln1 Tie2Cre mouse lungs. The number of cells co‐stained with α‐smooth muscle actin and periostin was drastically increased in the vessel wall of Egln1 Tie2 mouse lungs. CONCLUSIONS Our results demonstrate that endothelial PHD2 deficiency and resultant activation of HIF2α are responsible for pulmonary vascular fibrosis in the newly discovered mouse model of PAH with obliterative vascular remodeling and progressive right heart failure. We also showed that in vivo PHD2 deletion increases the number of myofibroblasts in the vessel wall. These studies defined an unexpected role of PHD2 deficiency in the mechanisms of vascular fibrosis associated with severe PAH. Thus, targeting PHD2/HIF‐2α signaling is a promising strategy to reverse vascular fibrosis for treatment of severe PAH and promote survival.

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension

Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α

Inhibition of Anaplerosis Attenuated Vascular Proliferation in Pulmonary Arterial Hypertension

Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension Via Mtorc1 Signaling

PDGF-BB/KLF4/VEGF Signaling Axis in Pulmonary Artery Endothelial Cell Angiogenesis

PDZ‐Binding Kinase Drives Pulmonary Artery Smooth Muscle Proliferation and Vascular Remodeling in Pulmonary Arterial Hypertension

Abstract 10845: Akt-Dependent Vacuolar Protein Sorting 34 Activation Promotes Pulmonary Vascular Smooth Muscle Cell Proliferation and Survival in Pulmonary Hypertension

PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension

PPARδ Agonist GW501516 Inhibits PDGF-stimulated Pulmonary Arterial Smooth Muscle Cell Function Related to Pathological Vascular Remodeling.

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Hif2 Alpha is Required for the Development of Pulmonary Vascular Fibrosis Associated with Pulmonary Arterial Hypertension

Abstract 14033: Inhibition of the Prolyl Isomerase Pin1 Improves Endothelial Function and Attenuates Vascular Remodelling in Pulmonary Hypertension by Inhibiting TGF-β Signalling

Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1<alpha> signaling pathway.

Platelet-Derived TGF (transforming Growth Factor)-β1 Enhances the Aerobic Glycolysis of Pulmonary Arterial Smooth Muscle Cells by PKM2 (pyruvate Kinase Muscle Isoform 2) Upregulation

PDGF Promotes the Warburg Effect in Pulmonary Arterial Smooth Muscle Cells via Activation of the PI3K/AKT/mTOR/HIF-1α Signaling Pathway

Endothelial and Smooth Muscle Cell Interaction Via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension

Increased Glycolysis Contributes to Pulmonary Vascular Remodeling via ERK-dependent Calpain Activation in Pulmonary Arterial Hypertension

Inhibition of Overactive Transforming Growth Factor–β Signaling by Prostacyclin Analogs in Pulmonary Arterial Hypertension

Abstract 9804: Overexpression of Pericyte Hif2a Exacerbates Hypoxia Induced Pulmonary Hypertension and Right Ventricular Hypertrophy